Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of SIM0417/Ritonavir in Healthy Elderly Subjects
NCT05826249Phase 1Unknown
- Sponsor
- Simcere Pharmaceutical Group
- Start
- Apr 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of simnotrelvir in coronavirus disease 2019 (COVID-19), sponsored by Simcere Pharmaceutical Group. Primary endpoints: Maximum Plasma Concentration up to 72 hours, Area Under the Curve to Last Timepoint up to 72 hours and 5 more. Status: unknown.
02
Drugs
simnotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05826249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05826249.